These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 17437665)
21. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
22. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Nurmohamed MT; van Halm VP; Dijkmans BA Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923 [TBL] [Abstract][Full Text] [Related]
23. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Solomon DH; Glynn RJ; Rothman KJ; Schneeweiss S; Setoguchi S; Mogun H; Avorn J; Stürmer T Arthritis Rheum; 2008 Aug; 59(8):1097-104. PubMed ID: 18668605 [TBL] [Abstract][Full Text] [Related]
24. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563 [TBL] [Abstract][Full Text] [Related]
25. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785 [TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470 [TBL] [Abstract][Full Text] [Related]
27. Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Aneja A; Farkouh ME Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):53-66. PubMed ID: 19124408 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Huang WF; Hsiao FY; Wen YW; Tsai YW Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003 [TBL] [Abstract][Full Text] [Related]
29. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245 [TBL] [Abstract][Full Text] [Related]
30. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469 [TBL] [Abstract][Full Text] [Related]
31. [Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects]. Batlouni M Arq Bras Cardiol; 2010 Apr; 94(4):556-63. PubMed ID: 20498929 [TBL] [Abstract][Full Text] [Related]
33. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Fosslien E Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252 [TBL] [Abstract][Full Text] [Related]
34. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Kean WF; Buchanan WW Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. McGettigan P; Henry D JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831 [TBL] [Abstract][Full Text] [Related]
36. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction. Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950 [TBL] [Abstract][Full Text] [Related]
37. Cardiovascular risks of COX inhibition: current perspectives. Farooq M; Haq I; Qureshi AS Expert Opin Pharmacother; 2008 Jun; 9(8):1311-9. PubMed ID: 18473706 [TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 inhibitors in patients with high gastrointestinal risk: are we there yet? Wong VW; Chan FK J Gastroenterol; 2009; 44 Suppl 19():53-6. PubMed ID: 19148794 [TBL] [Abstract][Full Text] [Related]
39. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Amer M; Bead VR; Bathon J; Blumenthal RS; Edwards DN Cardiol Rev; 2010; 18(4):204-12. PubMed ID: 20539104 [TBL] [Abstract][Full Text] [Related]